Last $9.52 USD
Change Today -0.44 / -4.42%
Volume 1.1M
MACK On Other Exchanges
As of 8:10 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

merrimack pharmaceuticals in (MACK) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/9/15 - $12.00
52 Week Low
04/28/14 - $4.13
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

merrimack pharmaceuticals in (MACK) Related Bloomberg News

View More Bloomberg News

merrimack pharmaceuticals in (MACK) Related Businessweek News

No Related Businessweek News Found

merrimack pharmaceuticals in (MACK) Details

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Its therapeutic oncology candidates in clinical development include MM-398, a stable nanotherapeutic encapsulation of the chemotherapy drug irinotecan, which is in multiple ongoing Phase I, Phase II, Phase III clinical trials for the treatment of various cancers; MM-121, a human monoclonal antibody that targets the ErbB3 cell surface receptor, which is in multiple ongoing Phase I and Phase II clinical trials to inhibit cancer growth directly; and MM-111, a bispecific antibody that is in multiple ongoing Phase I and Phase II clinical trials to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor. The company’s product candidates also include MM-302, an antibody drug conjugated liposomal doxorubicin that is in Phase I clinical trials for advanced ErbB2 positive breast cancer; MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, which is in Phase I clinical trials for refractory solid tumors; and MM-141, a human tetravalent bispecific antibody that is in Phase I clinical trials to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth factor 1 receptor(IGF-1R) and ErbB3. Its therapeutic oncology product candidates are used in the treatment of various cancers, including pancreatic, colorectal, gastric, glioma, ovarian, breast, lung, and other gynecological cancers. The company has collaboration and license agreements with Actavis, Sanofi, PharmaEngine, Inc., Dyax Corp., Adimab LLC, University of California, U.S. Public Health Service, and Selexis SA. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

254 Employees
Last Reported Date: 03/4/14
Founded in 1993

merrimack pharmaceuticals in (MACK) Top Compensated Officers

Chief Executive Officer, President, Executive...
Total Annual Compensation: $512.7K
Co-Founder, Chief Scientific Officer and Seni...
Total Annual Compensation: $364.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $284.6K
Senior Vice President of Corporate Operations
Total Annual Compensation: $343.3K
Senior Vice President of Business Development...
Total Annual Compensation: $305.7K
Compensation as of Fiscal Year 2013.

merrimack pharmaceuticals in (MACK) Key Developments

Merrimack Pharmaceuticals, Inc. Announces Executive Changes, Effective January 30, 2015

On January 15, 2015, Ulrik B. Nielsen provided notice of his resignation as Senior Vice President and Chief Scientific Officer of Merrimack Pharmaceuticals, Inc. (the Company), effective as of January 30, 2015. On January 19, 2015, Anthony J. Sinskey provided notice of his resignation from the Company's Board of Directors (the Board), effective as of January 30, 2015. Dr. Sinskey will continue to serve the Company as a scientific advisor. On January 20, 2015, the Board elected Dr. Nielsen as a director of the Company, effective as of January 30, 2015, to fill the vacancy created by the resignation of Dr. Sinskey.

Merrimack Pharmaceuticals, Inc. Board Changes, Effective January 31, 2015

Merrimack Pharmaceuticals, Inc. announced that Birgit M. Schoeberl, Ph.D. has been named the new head of its Discovery division. Ulrik B. Nielsen, Ph.D. will be stepping down as the head of the Discovery division and has been elected to serve on the company's board of directors. Anthony J. Sinskey, Sc.D. will also be resigning from the board of directors and will continue as a scientific advisor. All of these transitions will occur on January 30, 2015. Nielsen has been elected to serve on the company's board of directors, effective January 30, 2015. Prior to joining the company, Nielsen trained at University of California, San Francisco, and MIT.

Merrimack Pharmaceuticals and PharmaEngine Report Positive Phase III Results for MM-398 in Pancreatic Cancer

PharmaEngine and its partner Merrimack Pharmaceuticals have presented additional analyses from a global, randomised, open-label Phase III (NAPOLI-1) trial investigating the safety and efficacy of MM-398 (liposome irinotecan injection) in metastatic pancreatic cancer. The analyses of the trial lend further support to the positive top-line data that were presented in 2014 demonstrating a statistical increase in overall survival (OS) following treatment with MM-398 and 5-fluorouracil and leucovorin (5-FU/LV), with a hazard ratio of 0.67 (p=0.01) and a median OS of 6.1 months, compared with 4.2 months with 5-FU/LV alone. In the expanded analyses, the OS for MM-398 hazard ratio was 0.57 (p=0.0009) in the stratified analysis that accounts for pre-specified prognostic factors, while the analysis of the per protocol population, or those patients who received 80% of protocol-defined dose and remained on treatment for at least six weeks demonstrated more statistical improvement in median OS (8.9 months) compared with the control arm (5.1 months; p=0.0018). In addition, the trial revealed significant improvements in progression-free survival, objective response rate, and CA19-9 tumour market response following treatment with MM-398 compared with the control arm. The data were presented at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology on 16 January 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MACK:US $9.52 USD -0.44

MACK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MACK.
View Industry Companies

Industry Analysis


Industry Average

Valuation MACK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERRIMACK PHARMACEUTICALS IN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at